SCHEMBL166021

SCHEMBL166021

CC1CCCc2ccc(Cl)cc2N1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 6/20 0.41
▸ HTR2B P41595 6/20 0.41
▸ HTR2A P28223 5/20 0.41
▸ SLC6A4 P31645 3/20 0.41
▸ ADRB1 P08588 1/20 0.41
▸ HTR1A P08908 1/20 0.41
▸ ADRA2A P08913 1/20 0.41
▸ ADRA2B P18089 1/20 0.41
▸ ADRA2C P18825 1/20 0.41
▸ CNR1 P21554 1/20 0.41
▸ SLC6A2 P23975 1/20 0.41
▸ HRH1 P35367 1/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ CMA1 P23946 1/20 0.39
▸ AHR P35869 1/20 0.39
▸ KDM1A O60341 2/20 0.37
▸ SRD5A1 P18405 1/20 0.37
▸ SIRT1 Q96EB6 3/20 0.36
▸ SIRT2 Q8IXJ6 2/20 0.36
▸ SIRT3 Q9NTG7 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28618675 0.89 HTR2C (0.44) HTR2CHTR2BHTR2ASLC6A4ADRB1
SCHEMBL7897325 0.78 CMA1 (0.43) HTR2CHTR2BHTR2ASLC6A4ADRB1
SCHEMBL10841091 0.77 HTR2C (0.41) HTR2CHTR2BHTR2ASLC6A4ADRB1
SCHEMBL29659975 0.77 HTR2C (0.41) HTR2CHTR2BHTR2ASLC6A4ADRB1
SCHEMBL166058 0.77 MAPT (0.43) MAPT
SCHEMBL30853463 0.71 HTR2A (0.47) HTR2CHTR2BHTR2ASLC6A4ADRB1
SCHEMBL3873031 0.71 HTR2A (0.47) HTR2CHTR2BHTR2ASLC6A4ADRB1
SCHEMBL23812633 0.70 TSHR (0.41) MAPT
Hydrochloric Acid SCHEMBL11332118 0.70 HTR2C (0.39) HTR2CHTR2BHTR2AHTR1AADRA2A
SCHEMBL25058873 0.69 HTR2A (0.46) HTR2CHTR2BHTR2ASLC6A4ADRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611449-A1 ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT Arena Pharmaceuticals, Inc. (US) 2013-07-10 — — EP disclosed
WO-2012030939-A1 ADMINISTRATION OF LORCASERIN TO INDIVIDUALS WITH RENAL IMPAIRMENT ARENA PHARMACEUTICALS, INC. (US) 2012-03-08 — — WO disclosed
Send feedback